Prostate Cancer: MP-MRI Recommended as Diagnostic Test

Share this content:
Multi-parametric Magnetic Resonance Imaging (MP-MRI) may be an accurate method of diagnosing clinically-significant prostate cancer.
Multi-parametric Magnetic Resonance Imaging (MP-MRI) may be an accurate method of diagnosing clinically-significant prostate cancer.

Multi-parametric Magnetic Resonance Imaging (MP-MRI) may be an accurate method of diagnosing clinically-significant prostate cancer that avoids complications associated with biopsy, according to a study published in The Lancet.1

Transrectal ultrasound guided biopsy (TRUS-biopsy) is frequently used after an elevated serum prostate-specific antigen (PSA), though the procedure is associated with serious adverse events including sepsis. For this study (ClinicalTrials.gov Identifier: NCT01292291), researchers assessed whether MP-MRI would be an effective component of a “triage” diagnostic procedure, using template prostate mapping biopsy (TPM-biopsy) as a reference.

Of 740 enrolled participants with an elevated PSA within the previous 3 months, a “suspicious” digital rectal or rectal examination, or a family history of prostate cancer, 576 underwent the diagnostic “triage” of MP-MRI followed by TRUS-biopsy and TPM-biopsy.

MP-MRI had a sensitivity of 93% and a negative predictive value of 89% for clinically-significant cancer: of 158 participants who had a negative MP-MRI, 17 had clinically significant cancer. TRUS-biopsy had only 48% sensitivity and a 74% negative predictive value.

RELATED: Prostate Cancer: Future of Research and Treatment

The authors concluded that MP-MRI may reduce unnecessary biopsies by 27%, as well as avoid 5% of insignificant cases of prostate cancer. Biopsies directed by MP-MRI results would improve diagnostic accuracy overall.

There were 8 cases of sepsis and 44 total cases of serious adverse events among the initially-enrolled 740 participants. 

Reference

  1. Ahmed HU, Bosaily AE, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. 2017 Jan 19. doi: 10.1016/S0140-6736(16)32401-1 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters